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Prognostic and Predictive Factors 
in Newly Diagnosed Multiple 
Myeloma Patients with Early 
Mortality with Prediction Matrix 
and Three and Five-Year Overall 
Survival
Howard R. Terebelo and Leo Reap
Abstract
Survival rates for newly diagnosed multiple myeloma have increased to a 
remarkable 8–12 years. Novel agents, autologous stem cell transplantation, mono-
clonal antibodies, improvements in supportive care and attention to minimal resid-
ual disease negative all have aided this remarkable journey. With these treatments 
we are identifying tools to achieve complete remissions. Prognostic factors have an 
important role in selecting proper patient approaches for trial designs. Prognostic 
and predictive clinical biomarkers have shaped staging and treatment selections for 
newly diagnosed multiple myeloma. Here we review the Early Mortality Prediction 
Matrix to identify those at risk of an early death (<6 months) incorporating both 
disease biology with patient fitness. We also review current standards of care for 
multiple myeloma and provide a three and five-year overall survival prediction 
matrix. We review benefits for MRD negativity and Next-Gen Sequencing. These 
tools will help clinicians improve upon reducing early mortality in newly diagnosed 
multiple myeloma patients and provide further framework for improving survival 
by assessing clinical, biologic and individual multiple myeloma patients.
Keywords: newly diagnosed multiple myeloma, prediction matrix, 
prognostic factors, prediction factors, progression-free survival, early mortality, 
novel agents, next-gen sequencing, overall survival
1. Introduction-early mortality
The current era of advances in multiple myeloma (MM) identifies a subset of 
newly diagnosed multiple myeloma (NDMM) patients with early mortality (EM) 
within the first 6 months of diagnosis [1–6].
Prognostic and predictive risk factors have been identified by the International 
Myeloma Working Group (IMWG) based upon the LDH, international staging 
system (ISS), Stage III disease and adverse cytogenetics [7]. Limitations of this 
study include patients limited to autologous stem cell transplantation (SCT) 
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which included only 40% of all patients. Prediction matrix models based upon 
those created for cardiovascular disease and rheumatoid arthritis [8, 9] which can 
calculate the risk of specific outcomes such as mortality allowing the differential 
weighting of risk factors. We can identify patients at risk with NDMM for EM to 
provide insight in applying different treatment approaches. Prediction tools have 
been applied in other hematologic malignancies to predict EM. In AML, prediction 
factors have improved treatment paradigms [10]. In diffuse large B-cell lymphoma, 
cell of origin and molecular markers along with PET scans have provided earlier 
treatment interventions to improve outcomes [11, 12].
Real World patients often differ from those enrolled in clinical trials. These 
patients tend to be older and less fit, have more co-morbidities and less often SCT 
candidates [13]. An observational patient registry allows broad patient charac-
teristics and treatment outcomes while assessing NDMM patient characteristics, 
biology, co-morbidities and treatments for progression-free survival (PFS) and 
overall survival (OS) [13–16].
2. Early mortality in the Connect MM Registry
The Connect MM Registry reported on more than 3000 NDMM to identify and 
characterize EM. The first cohort included the first 1500 patients. Data was collected 
from an unselected patient population from routine clinical practices (81% commu-
nity and 18% academic). Here a prognostic tool to assess the risk of EM based upon 
weighting of risk factors in elderly, SCT and non-SCT eligible patients was created 
to construct an Early Mortality Prediction Matrix (EMPM). See Figure 1.
For the 102 NDMM patients with EM, 39.2% (2.7% of total enrolled) were 
due to MM progression and 32.9% were related to non-causes. Common causes of 
death included heart failure, pneumonia, infections, and renal failure. The other 
Figure 1. 
A color-coded guide for the clinician identifies which patient (in red) who are at highest risk for EM within six 
months of diagnosis compared to green and yellow patients who are lowest risk.
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28.4% died of other causes or unknown. For those patients surviving more than 
six months causes of deaths were due to MM (58%) with 5% due to non-myeloma 
causes. The patients with EM received less triplet therapy (30% vs. 44.7%) and 
more radiation (24.5% vs. 15.3%) compared with longer surviving patients. EM 
patients were sicker and less likely to receive triplet therapy.
3. Conclusions
Prior to the era of novel agents, the incidence of EM in NDMM was 10–14% 
[1, 5, 17, 18]. Novel agents, supportive care, and SCT have improved PFS and OS. 
The promise of CAR-T therapy, monoclonal antibodies and unique agent BCMA 
directed against tumor necrosis super family member 17 suggest ongoing improve-
ment for NDMM patients. Key management issues and controversies in EM patients 
in NDMM patients were passionately presented by Gonsalves [19]. Here the authors 
defined EM occurring in phase III trials and outlined key management issue strate-
gies for NDMM to mitigate EM and summarizing those patients most at risk. The 
EMPM here describes parameters to identify NDMM patients at risk for EM, pitfalls 
in treatment and opportunities to formally address EM in clinical trials.
The prognosis of NDMM patients depends upon staging, patient features, 
disease biology and treatment outcomes [3]. Risk stratification utilizes the Revised-
International Staging System (R-ISS) as devised by the IMWG. The R-ISS is appli-
cable for long-term prognosis but cannot identify those at risk for EM with NDMM 
[20]. Issues with the R-ISS include a point-based system which is disease specific 
factors which cannot assess the relative individual of each factor and does not 
account for patient-specific risk factors. The frailty score, as in the R-ISS, is a point-
based system that combines age, functional status and co-morbiditites to predict 
long-term survival and treatment feasibility in elderly patients with NDMM [20]. 
Combining the frailty score with the R-ISS stage improves the prognostic value 
for each score to predict long-term survival. However, neither score alone or when 
combined has been used to predict NDMM patients at highest risk for EM.
Prognostic studies provide clinicians with a better understanding of the relation-
ship in NDMM patients between the aggressiveness of disease and survival. There 
are significant gaps in our understanding the optimum ways to risk-stratify NDMM 
patients when incorporating patient and disease-specific risk factors along with 
combining the relative contributions of individual risk factors. Existing point-based 
systems make it difficult to accurately predict outcomes in patients who have a 
combination of standard and high-risk characteristics [20–23]. Additionally, point-
based models are primarily based upon data from interventional clinical trials that 
may not be representative of Real World NDMM patient populations. The EMPM 
model here allows differential weighting of the impact of the individual patients 
and disease-specific risk-factors [24–29].
Patient co-morbidities have been associated with higher mortality in various 
clinical trials of patients with MM [4, 30–37]. For some NDMM patients, co-
morbiditites are both a direct cause of death and places patients at risk for early 
disease-related mortality by limiting their ability to tolerate therapy [4, 31, 33, 34]. 
Though the decline the EM to 6.8% reflects the benefit of novel agents and sup-
portive care there are other considerations here. NDMM patients with EM tend to be 
older and poorer in health with higher rates of co-morbidities (especially diabetes), 
greater burden of disease, and high-risk features cytogenetics and Stage III disease. 
The EMPM demonstrates that a lower mobility score, age > 75, history of hyperten-
sion, thrombocytopenia, higher ECOG performance status, high ISS disease stage 
and renal insufficiency were associated with a higher likelihood of EM. Multivariate 
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analysis did not independently find anemia, del(17q) mutation, low self-care score 
from EQ-SD, hypercalcemia, diabetes and R-ISS score, beta-2 microglobulin and 
albumin did not predict EM. NDMM patients with EM received more radiation 
therapy which delayed the initiation of therapy and limited their ability to receive 
triplet therapy. The EMPM has been validated by bootstrapping for internal cross- 
validation [38–40]. A high degree of concordance was observed when applying 
the model using data from patients form the Phase 3 MM-015 trial and the phase 3 
FIRST trial despite more rigorous eligibility criteria [41].
This matrix has the potential to be a clinically useful tool for NDMM patients 
who are at risk for EM and for analyses of specific patient populations, selection of 
therapy, identification of new targets for treatment and standardized comparisons 
between trials.
High-quality systematic research to identify patients at risk for EM have not been 
studied prospectively. The EMPM is the first weight-based model that accounts 
for both patient and disease-specific risk factors. This model can facilitate early 
recognition for NDMM patients at high risk for EM to assist physician selection of 
personalized treatments, avoidance of nephrotoxic agents, monitoring of steroid 
dosing in diabetic patients, prompt initiation of doublet or triplet therapy and 
limiting radiation fields when applicable and the use of prophylactic antibiotics. The 
EMPM can be applied in routine clinical practice and considered in a risk-adaptive 
approach. Clinical trials of reducing EM patients in NDMM can be designed for new 
areas of research.
4. Three and five-year overall survival in NDMM
Over the past 60 years, dramatic changes have been made in the treatment of 
multiple myeloma. These advances have radically altered the disease landscape and 
prognosis for newly diagnosed patients, turning a previously untreatable illness 
toward one of a chronic disease [42]. Here we discuss a brief history of treatments 
and prognostic features in NDMM, the development of novel treatment regimens, 
and the use of a prediction matrix in 3-year, and 5-year overall survival (OS).
4.1 Historical background of prognostic features
In 1850, Dr. Henry Bence Jones described the first case of myeloma. His patient 
presented with fatigue, arthralgias, and polyuria. His urine was found to precipi-
tate an unusual protein upon healing, now known as Bence Jones protein. In 1873, 
Rustizky was found to have multiple osseous masses in a similar patient, giving 
rise to the name multiple myeloma. In 1889, Kahler presented a large review of the 
disease, leading it to be called Kahler disease. Over the subsequent several decades, 
advances in x-ray imaging, microscopy, and electrophoresis allowed for further 
characterization of the disease. In 1953, immunoelectrophoresis identified excess 
monoclonal heavy and/or light chains as characteristic for the disease process seen 
in multiple myeloma [43]. 
Untreated, NDMM has a median overall survival of two years. In 1958, Blokhin 
introduced chemotherapy in MM with a mixture of racemic phenylalanine and 
nitrogen mustards like sacrosine. In 1962, Bergsagel pioneered the use of melphalan 
and glucocorticoids, creating the combination of melphalan with prednisone (MP), 
still in use today. However, complete remissions (CR) were rare. In 1983, McElwain 
and Powles introduced the use of high-dose therapy with melphalan, with CR 
achieved in a proportion of patients [44]. Those who achieved CR with MP had a 
median survival of eight years.
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Despite the initial advances, the median OS remained at about three years. 
Remarkably, the current median OS now ranges from 8 to 12 years [45]. However, 
individual outcomes are varied, with 20% of patients surviving less than 2 years 
and 40% surviving more than 10 years after diagnosis [46]. Considerable advances 
in understanding of the pathobiology of multiple myeloma over this time have 
greatly aided in the ability to select prognostic factors in NDMM. Advances in treat-
ment that have been contributed greatly to survival are reviewed below.
4.2 Prognosis in NDMM
For many years, the factors contributing to the highly variable prognosis in 
myeloma were unclear. Early on, immunoglobulin isotype was shown to play a 
role in prognosis, with monoclonal 1gA production (21%) associated with a worse 
prognosis [47]. The degree of plasma cell burden is only an issue in plasma cell 
leukemia [48, 49].
In 1975, the Durie-Salmon staging system was adopted, stratifying individuals 
by relative plasma cell burden (anemia), hypercalcemia, number of lytic lesions 
visible on x-ray, and serum urine M-protein levels [50]. However, the number of 
lytic lesions on x-ray is observer-dependent and created challenges with respect to 
enrollment and reproducibility between trials.
Thirty years later in 2005, Griepp and colleagues established the international 
staging system (ISS), utilizing the beta-2 microglobulin level and albumin level to 
appropriately risk-stratify patients. The ISS can predict EFS and OS regardless of 
age, geographic region, study site, standard-dose vs. high-dose therapy (HDT), or 
the use of novel agents [51].
Discovery of specific cytogenetic abnormalities correlates with prognosis in 
multiple myeloma and overall survival. Plasma cells typically have a low-prolif-
erative index, and so cytogenetic abnormalities are detected in a small number of 
patients. Interphase FISH was found to be useful in identifying specific cytogenetic 
aberrations [52].
4.3 1gH rearrangements
As the heavy chain of the immunoglobulin molecule is constitutively activated 
on the 14th chromosome within plasma cells, translocations involving the immuno-
globulin heavy chain haven been shown to play a strong role in myeloma pathogen-
esis and occur in up to half of NDMM patients. Among these 1gH translocations, 
five appear to be recurrent: t(4;14) and t(11;14), t(4;16) and t(14;20) [53]. The 
translocations t(4;14) and t(11;14) are not the most common abnormalities involv-
ing the 1gVH gene in myeloma, each seen in approximately 15% of patients. These 
translocations lead to overexpression of FGRF3 and BCL2, respectively. T(4;14) is 
regarded as high-risk abnormality with inferior median OS. t(11;14) and hyper-
diploidy have been reported in some studies to predict a more favorable outcome. 
T(11;14) is observed in 16–24% of MM patients and has specifically gained interest 
with the use of the novel agent venetoclax, a BCL2 inhibitor. Currently, the use of 
venetoclax was stopped due to an early signal for increased death in early clinical tri-
als due to a higher rate of infections [54]. A large, US, multicenter prospective obser-
vational cohort study did not demonstrate any impact of t(11;14) on PFS, or OS 
[55]. Further clinical trials investigating its use in myeloma are currently pending. 
T(14;16) and T(14;20) are relatively rare, seen in approximately 1.5–3% of patients 
and lead deregulation of the oncogenes c-MAF and MAFAB, respectively. Though a 
pivotal trial from the Mayo Clinic was suggestive of poor prognostic correlation with 




Though commonly seen in association with other cytogenetic abnormalities in 
NDMM, del(13) alone does not predict poor outcomes. When occurring in MGUS 
and SMM it does not influence progression to myeloma. The finding has called 
into question the use of del(13) in NDMM prognostication [56]. However in the 
presence of concomitant t(4;14) or del17p, poor prognosis is suggested
del(17p).
The loss of the short term arm of chromosome 17, or del(17p), leads to loss of 
TP53 and appropriate DNA repair. 17p deletions occur in 8–10% of NDMM patients 
and has remained a poor risk feature not over by current use of novel therapies. 
Without adequate DNA repair function, the rate of clonal mutagenesis and sub-
sequent treatment resistance rises more rapidly. Del(17p) is acquired at a median 
of 35.6 months after the time of diagnosis, with a median PFS of 5.4 months after 
acquisition. Consequently, as compared to non-del(17p) patients, median OS is 
significantly worse [57, 58].
4.5 Hyperdiploidy and other cytogenetic abnormalities
In recent years, high-throughput genomic studies using SNP or CGH arrays have 
accelerated our understanding of genetic changes within NDMM. Hyperdiploidy 
generally confers a more favorable prognosis in NDMM. The presence of certain 
trisomies, such as trisomy 3 and trisomy 5, may partially abrogate the negative 
prognostic features of other cytogenetic abnormalities. In contrast, the presence 
of trisomy 21 may potentiate the effects of negative prognostic features. Recently 
identified chromosomal abnormalities, such as gain of 1q and loss of 1q have also 
been shown to predict for poorer outcomes. One univariate analysis identified 
poorer prognosis with deletions of 1p, 2p, 14q, 16q, and 22q. Conversely, amplifica-
tions of chromosome 5, 11, 15 and 19 were associated with improved outcomes 
[56]. Chromosome 1q gain has become the most important chromosomal gain 
abnormality. In a recent update, high risk cytogenetics are presently considered to 
be del(17p), a p53 mutation, t(4;14), t(14;16),or gain 1q [59]. Similar to lymphoma, 
the presence of any two or three risk factors is considered ‘double-hit’ or ‘triple-hit’ 
myeloma, respectively.
In 2015, with the advent of cytogenetic profiles, a revised version of the ISS 
(R-ISS) was adopted, incorporating LDH and high-risk cytogenetics of t(4;14), 
t(14;16), and del(17p) into the scoring system [60, 61]. These objective systems 
have allowed for more reproducible results and the ability to more accurately 
compare patients within clinical trials [61].
However, establishment of baseline disease characteristics are critical for long 
term prognosis [62]. These newer staging systems do not account for several fea-
tures that have been shown to correlate to long-term outcomes in myeloma, such as 
the use of novel myeloma therapies, triplet therapy, autologous stem cell transplant, 
patient performance status, renal function, a history of diabetes, or MRD status.
Novel agents in multiple myeloma have allowed for significant progress in the 
treatment of newly diagnosed patients, with more than doubling of the average 
survival with less toxicity [47].
a. Alkylating agents
In the early 1960’s melphalan and cyclophosphamide were the first alkylating 
agents introduced in the treatment of NDMM demonstrated equivalent activ-
ity. In 1972, Harley evaluated other alkylating agents in NDMM, with the use 
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of melphalan, carmustine, and cyclophosphamide, melphalan and prednisone. 
(MP) was established as the gold standard for treatment, paving the way to 
several decades of comparison against other combinations of agents, includ-
ing cyclophosphamide, carmustine, vincristine, and adriamycin. Ultimately, 
combination therapies improved the response rate in NDMM but did not 
improve OS compared to MP. MP has a response rate of 50–60%, median 
PFS of 18 months, and an OS of 30–60 months [63]. To date, melphalan and 
cyclophosphamide remain effective treatment options and are commonly used 
in autologous stem-cell transplant conditioning. Combination alkylating agent 
regimens (such as VD-PACE or VDT-PACE) remain typically reserved for more 
aggressive disease, as in plasma cell leukemia or refractory MM.
b. Glucocorticoids
Glucocorticoids directly induce apoptosis of plasma cells. This is believed to 
occur via induction of IkB production that negatively regulates NFkB, result-
ing in downregulation of IL-6 and other pro-inflammatory cytokines, which 
facilitates apoptosis of the myeloma clones. In the late 1960’s prednisone was 
added to melphalan, but adoption was slowed due to concerns over the known 
osteoporosis effect of chronic steroid therapy [44]. Since then, glucocorticoids 
(particularly dexamethasone) have remained a backbone of therapy. Single-
agent dexamethasone is no longer advocated in the treatment of NDMM.
c. IMiDs
An international, randomized phase III trial demonstrated that thalidomide 
with dexamethasone was superior to dexamethasone alone, with an ORR or 
63% vs. 46% and a PFS of 14.9 months vs. 6.5 months [59]. FDA approval 
in the USA in 1998 of Thalidomide was cautiously accepted due to historical 
concerns regarding the drug-associated phocomelia was displayed in infants 
30 years earlier as antiemetic therapy in pregnancy. Thalidomide is used 
throughout Europe to date in the treatment of myeloma. Lenalidomide was 
FDA approved in 2005 based upon rate and lower toxicity profile on a retro-
spective single-institution case–control study of lenalidomide-dexamethasone 
vs. thalidomide dexamethasone demonstrated lenalidomide was better toler-
ated, had a higher ORR of 80% vs. 61%, higher VGPR rate 34 vs. 12%, and 
improved PFS of 27 months vs. 17 months, establishing lenalidomide with 
dexamethasone as an appropriate induction option [64]. In 2013, pomalido-
mide, a second-generation IMiD, was developed for use in relapsed/refractory 
disease. Though shown to have clear activity in NDMM via several immuno-
modulation pathways, the precise mechanism of action of these agents remain 
elusive. Irreversible peripheral neuropathy and increased thrombotic risk 
remain primary side effects of these agents. Prophylaxis with low-dose aspirin 
daily is adequate prevention.
d. Proteasome inhibitors
The primary function of plasma cells is to produce immunoglobulin, which 
occurs on a constitutive basis and requires assembly within 26 s proteasome. 
Excess accrual of protein within the cell creates proteotoxic stress, leading to 
cell apoptosis and death. As a result, proteasome inhibitors have been shown to 
have potent efficacy within the treatment of myeloma. Bortezomib, a boron-
containing dipeptide, was the first proteasome inhibitor to be introduced for 
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the treatment of multiple-myeloma. Monotherapy bortezomib FDA approval 
in 2003 demonstrated an ORR of 27% and a 10% CR rate. In combination with 
dexamethasone, ORR improved to 88% and CR + VGPR rate of 19%, with a 
1-year OS of 87% [65]. Other proteasome inhibitors, including carfilzomib 
and ixazomib, have been developed and are FDA approved in the relapsed-
refractory setting.
Emerging novel agents and therapies
e. Within the past 5 years, several agents have become available in the treatment of 
multiple myeloma. Notable agents, Dartumumab, a monoclonal antibody against 
CD-38, has displayed promising efficacy. Belantamab mafadotin, an antibody-
drug conjugate between the B-cell maturation antigen (BCMA) and MMAF 
(a chemotherapy payload) was recently FDA approved for relapsed/refractory 
disease. BCMA CAR-T cell therapy also shows promise in the relapsed/refractory 
setting. Though not yet approved in NDMM, these agents, along with others, 
show promise in the treatment of newly-diagnosed and relapsed-refractory 
patients.
In 2005, OS in NDMM was 4.6 years, increasing to 6.1 years by 2010. Over the 
past decade, the adoption of immunomodulatory agents and proteasome inhibi-
tors in triplet therapy extended median OS to greater than 7 years. These gains 
were predominantly driven by triplet therapy in the elderly and by reducing early 
mortality in the disease [53, 66].
4.6 Triplet therapy
For many years, monotherapy or doublet regimens were commonly used in the 
treatment of NDMM. However, with the progressive development of the previously 
discussed treatment options over the past decades, numerous clinical trials have 
investigated their use in combination in two-, three-, and four-drug regimens in an 
attempt to achieve deeper reductions in clonal disease burden. Generally, three-
drug combinations (i.e., VCD, VRD, VTD) have been shown to derive the highest 
ORR and VGPR compared with two-drug regimens and remain the standard of care 
for fit patients prior to autologous stem cell transplantation (SCT). A Southwest 
Oncology Group trial randomized 525 patients to either RVD or RD and maintained 
on RD until progression, with the three-drug combination displaying a better 
median PFS of 43 months vs. 30 months and median OS 75 vs. 64 months (HR 0.7, 
p = 0.025). As part of triplet therapy, lenalidomide, bortezomib, and dexametha-
sone (RVD) currently remain standard of care for induction. Though the addition 
of a fourth drug has not yet shown clear benefit to date, its use likely marks the 
future, with daratumumab-containing regimens appearing promising. Recently, the 
GRIFFIN trial compared daratumumab with RVD vs. RVD in NDMM and demon-
strated that D-RVD significantly improved strict CR rates and MRD-negativity in 
transplant-eligible patients [67].
4.7 Autologous stem cell transplant
In the early 1980’s, high dose therapy (HDT) with melphalan followed by 
autologous stem cell transplant (SCT) was performed by McElwain on a patient 
with plasma cell leukemia. This demonstrated some benefit, but initial adop-
tion was limited due to toxicity of the transplantation process. In the late 1980’s, 
Barlogie further investigated the use of SCT and developed the framework for 
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SCT in the 1980’s and 1990’s as part of the standard of care for eligible patients 
following induction. This led to several prospective, randomized clinical trials in 
the 1990’s which demonstrated superior ORR, PFS, and OS in individuals up to 
age 65, whereas others demonstrated no survival advantage. Today, SCT following 
induction therapy in eligible patients remains standard of care. Steady advances in 
SCT outcomes have occurred over the past 30 years, with patients treated in 2014 
or later having superior OS and reduced excess risk for MM death. Second stem cell 
transplantation may be considered in those with progression-free survival (PFS) 
or more than three years. Similarly models have supported the potential for cure, 
estimated at 6.3% to 31.3% depending on the year of treatment [55]. Whether novel 
agents will supplant HDT followed by SCT backed by minimal residual disease 
(MRD) continues to be explored. Consideration of myeloablative regimens beyond 
high-dose melphalan is another venue to be explored for increasing and deepening 
the CR and MRD negative status.
4.8 Solitary plasmacytoma
Solitary plasmacytomas are uncommon and account for only 6% of all plasma 
cell neoplasms. They are defined as the presence of a single osseous lesion (medul-
lary) or in the soft tissue outside of the bone (extramedullary) without evidence 
of bone marrow, clonal plasmacytosis, or CRAB criteria. The incidence of solitary 
plasmacytomas has increased with increased radiographic imaging use over the 
past thirty years; incidence increased by 10% from 1999 to 2004 as compared to 
1992–1998. Patients with less than 10% plasma cells by bone marrow biopsy can be 
managed with therapies against the solitary lesion alone, typically 40–50 cGy of 
radiation or surgical excision alone depending on the location. These patients will 
eventually progress to MM over the subsequent years but have a generally favorable 
prognosis, with PFS 63% at 10 years. Extramedullary plasmacytoma has an even 
more favorable prognosis with myeloma-specific death seen in less than one-third 
of patients. Progression to MM typically occurs within 5 years from initial diagno-
sis. Features suggestive of high risk for progression include persistent monoclonal 
protein after treatment of the solitary lesion, detectable clonal plasma cells in the 
bone marrow, age 40–60 years old, and individuals of African-American descent. 
Despite the marked difference in long-term prognosis to NDMM, previous staging 
systems have not accounted for the presence or absence of solitary plasmacytoma at 
diagnosis [68].
4.9 Performance status
Baseline performance status has long been understood to play a prominent role 
in prognosis in NDMM, with unfit patients often remaining ineligible for SCT, the 
use of triplet therapy, and certain novel therapies. Without these therapies, disease 
control is less common, and outcomes are worsened. Furthermore, clinical trials 
commonly select for fit patients (typically.
ECOG 0–1), reducing the generalization of data to community setting, where 
less fit patients are encountered with greater frequency.
4.10 Renal function
Baseline renal function in NDMM patients is an essential part of long-term 
prognosis. Impaired renal function at baseline limits the usage of novel agents 
that can be administered, as many are renally cleared. Persistent renal dysfunc-
tion limits what therapeutic options are available and thus long-term outcomes 
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are worse [69]. As cyclophosphamide is hepatically cleared, cyclophosphamide, 
bortezomib, and dexamethasone remains standard induction regimen in indi-
viduals with compromised renal function. Melphalan, which is cleared through 
spontaneous hydrolysis, is another renal-independent therapeutic option. 
Previous risk-stratification systems have not addressed this conundrum with 
renal dysfunction.
4.11 Diabetes
Comorbidities present in NDMM patients play a strong role in what therapies 
may be available [70]. Diabetes mellitus, owing to concomitant progressive renal 
dysfunction and peripheral neuropathy, may limit the use or dose of certain novel 
therapies. Both IMiDs and proteasome inhibitors may worsen peripheral neuropa-
thy, potentially limiting the dose able to be given or as a class altogether depending 
on the severity of neuropathy. Diabetic nephropathy poses similar limitations.
4.12 Minimal residual disease
In every NDMM patient, there are an average of 3 to 5 clones present. These 
clones undergo mutations at varying degrees throughout the treatment course, 
with progression of disease presenting expansion of resistant clones over time. As a 
result, multiple myeloma is not considered to be a curable disease, and so an evolv-
ing treatment aim has been for maximal disease burden reduction [71]. The ability 
to reduce disease burden beneath the threshold of detection, known as minimal 
residual disease (MRD), has been shown to be an important prognostic indicator 
for survival and long-term outcomes. MRD has traditionally been detected by flow 
cytometry (sensitive to 104 cells) and next generation sequencing (NGS) (sensitive 
106 cells). An evolving consensus is that achieving MRD-negative status at the time 
of induction therapy should be the goal of therapy. Though not-yet involved in 
staging systems, MRD-focused treatment assessments are becoming increasingly 
important with time [72].
4.13 Next-generation sequencing
NGS when it comes to FISH (seq-FISH) has improved sensitivity and similar 
specifically relative to clinical FISH studies and appears to identify a higher number 
of high-risk NDMM patients. These studies are currently ongoing to incorporate 
into routine staging systems [4, 29].
4.14 Predictive models in NDMM
Multiple advances in long-term survival have been made over time, with the 
potential for cure by some models. Heterogeneity of prognostic factors in multiple 
myeloma makes accurate prognostication difficult on an individual level. As a 
result, the use of prediction matrix and prognostic tools have aided our ability to 
assess overall survival. Furthermore, owing to the selection bias present within 
clinical trials populations, survival estimates derived from clinical trials limit the 
applicability to all “Real World” patients. The CONNECT  registry was created as 
a prognostic model for OS in an unselected community and academic setting [66]. 
Prognostic models should take into account myeloma biology, patient comorbidities 
and include performance status and mobility assessment [73]. Next Gen Sequencing 
will offer a more comprehensive approach to treatment and the goal of a MRD 
negative NDMM patient.
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